---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023740"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:13:34.253233+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations

## Summary
- Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.
- Loss from operations improved to $1.3M in Q2 2025 versus $1.4M in the prior year quarter.
- Raised $2.4M net in April and June 2025 from sale of senior subordinated notes and warrants to Aditxt (ADTX).
- PHEXXI submitted for UAE marketing approval by licensee Pharma 1; SOLOSEC submission expected Q3 2025.
- Net loss per share was $(0.02) in Q2 2025 vs net income of $0.02 per share in Q2 2024.

## SEC filing metadata
- accession: 0001641172-25-023740
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/0001641172-25-023740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023740
- JSON: https://secwatch.observer/filing/0001641172-25-023740.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.